Amit G Singal,Kirema Garcia-Reyes,Robin K Kelley et al.
Amit G Singal et al.
The introduction of immune checkpoint inhibitors (ICIs) for hepatocellular carcinoma (HCC) has spurred interest in evaluating their use in earlier lines of therapy, including in combination with locoregional therapy for patients with interm...
Impact of SGLT2i and GLP-1RA on liver-related events in patients with MASLD and type 2 diabetes: A network meta-analysis [0.03%]
SGLT2i和GLP-1RA对MASLD合并2型糖尿病患者肝脏相关事件的影响：网络meta分析
Lu Li,Xianhua Mao,Chi Ho Lee et al.
Lu Li et al.
Background & aims: Glucose-lowering drugs (GLDs) including glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) have been broadly evaluated in patients with coexisti...
P NPLA3 and TM6SF2 exacerbate the impact of alcohol and metabolic dysfunction on liver fibrosis [0.03%]
PNPLA3和TM6SF2加剧了酒精和代谢功能障碍对肝纤维化的影响
Sophie Gensluckner,Helle Lindholm Schnefeld,Jan Embacher et al.
Sophie Gensluckner et al.
Background & aims: Genetic predisposition (especially variants in PNPLA3 and TM6SF2), metabolic dysfunction, and alcohol consumption are established risk factors for steatotic liver disease (SLD) and progression of fibros...
Liver biopsy quality criteria to exclude cirrhosis in case of suspicion of porto-sinusoidal vascular disorder [0.03%]
疑似porto-窦性血管病时排除肝硬化的肝活检质量标准riteria
Chloé de Broucker,Valérie Paradis,Maria Luisa Botero et al.
Chloé de Broucker et al.
Background & aims: Baveno VII guidelines based porto-sinusoidal vascular disorder (PSVD) diagnosis on a liver biopsy excluding cirrhosis. However, evidence-based quality criteria for liver biopsy are lacking. This study a...
Interleukin-18 binding protein deficiency results in gut microbiota dysbiosis and aggravated diet-induced MASH in mice [0.03%]
白细胞介素-18结合蛋白缺乏导致小鼠肠道菌群失调和饮食诱导的代谢异常恶化
Emmanuel Somm,Elodie Perroud,Yunju Jo et al.
Emmanuel Somm et al.
Background & aims: Metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH) are now the most prevalent hepatic disorders worldwide. Growing evidence implicat...
Corrigendum to 'Primary percutaneous stenting for palliative biliary drainage of patients with malignant hilar biliary obstruction: TESLA trial' [JHEP Reports 7 (2025) 101541] [0.03%]
“经皮胆道支架植入术治疗恶性肝门部胆管梗阻患者：TESLA试验”一文的勘误通知
Stijn Franssen,Merve Rousian,Victorien van Verschuer et al.
Stijn Franssen et al.
[This corrects the article DOI: 10.1016/j.jhepr.2025.101541.]. © 2025 The Author(s).
Disease-modifying effect of efruxifermin in compensated cirrhosis due to MASH: To miss the forest for the tree(s) [0.03%]
MASH代偿期肝硬化中Efruxifermin的疾病修正作用：因树木而忽视森林？
Mattias Mandorfer,Georg Semmler
Mattias Mandorfer
Su Wang,Catherine Freeland,Seng Gee Lim et al.
Su Wang et al.
The terminology used to describe chronic hepatitis B (CHB) infection remains inconsistent and fragmented across liver societies, clinical settings, and research domains. This lack of alignment poses barriers to care, complicates clinical tr...
Corrigendum to "Peginterferon-alpha-2a add-on to treatment with siRNA JNJ-73763989 in virologically suppressed chronic hepatitis B: The phase II PENGUIN study" [JHEP Reports 2025 7(10) 101516] [0.03%]
对“PEG干扰素α-2a联合siRNA JNJ-73763989治疗病毒学抑制的慢性乙型肝炎患者的II期PENGUIN研究”[JHEP报告2025 7(10) 101516]的勘误
Edward Gane,Ewa Janczewska,Tetsuo Takehara et al.
Edward Gane et al.
[This corrects the article DOI: 10.1016/j.jhepr.2025.101516.]. © 2025 The Author(s).
From queues to questions: Reflections on EASL's Love Your Liver campaign in Amsterdam [0.03%]
从排队到提问——在阿姆斯特丹欧洲肝脏研究学会“关爱肝脏”活动的反思
Sarwa Darwish Murad,Maraika Black,Shira Zelber-Sagi et al.
Sarwa Darwish Murad et al.